ADMIT THERAPEUTICS, SL
A Healthtech, Business Services & Software startup included in the Barcelona & Catalonia Startup Hub
ADMIT
ADMIT THERAPEUTICS, SL
Carretera Laureà Miró, 408-410 08980 Sant Feliu de Llobregat
https://www.admit-therapeutics.com/
ADmit therapeutics is a company that has developed the MAP-AD Test, an IVD that provides a prognosis of progression from MCI to AD dementia. Our IVD is based on the analysis of blood mitochondrial methylcytosines using Next Generation Sequencing techniques and a machine learning approach, providing a prognosis which is not dependent on the b-amyloid or tau determination. The MAP-AD Test has obtained the CE IVDR mark, and the laboratory is certified by the College of American Pathologists.
Industries & Technologies
Financial data
Other information
Funding
(January 2025)
Capital
Investors: Clave Capital, Ship2B, WA4Steam
5.4M € (October 2023)
Seed
Investors: Sabadell BStartup,Ship2B Foundation,EIT Health,European Innovation Council,Capital Cell,"la Caixa" Foundation,bellvitge biomedical research institute - idibell,Ship2B Ventures,Clave Capital,EIC Fund,Genesis Biomed,WA4STEAM,Lavanda,Alzheimer's Drug Discovery Foundation
Source: Press releases newsletters & platforms company websites annual reports & accounts regulatory body sites & stock exchanges
@admittherapeut1
Other startups near startup ADMIT
similar companies
- Healthtech
- Business Services & Software
- Gov tech & Security
- AI & Big Data
- Digital Health
- Biotechnology
- Industry 4.0
- Deeptech
- Scaleup
- Healthtech
- Business Services & Software
- AI & Big Data
- Cloud & Edge Computing
- Omic Sciences
- Vaccines & New biological design
- Biotechnology
- Industry 4.0
- Deeptech
- Scaleup
Collaborators of Barcelona & Catalonia Startup Hub.
We teamed up with business associations, universities and startup incubators to create the Barcelona & Catalonia Startup Hub.